INTRODUCTION {#s1}
============

Carcinoma of unknown primary origin (CUP), also known as occult primary tumor is defined as histologically proven metastatic malignant tumors whose primary site cannot be identified by clinical manifestation, radiographic and pathologic examinations \[[@R1], [@R2]\]. It comprises heterogeneous groups of tumor, clinically and histologically and about 3% to 5% of all newly diagnosed malignant tumors are classified as CUP \[[@R2]\].

Among CUPs, adenocarcinoma comprises the most common histologic type in reported studies \[[@R3], [@R4]\]. Generally, patients of CUP have poor clinical prognosis with limited life expectancy. Median survival of 3 months in extranodal adenocarcinoma and 8 months in metastatic adenocarcinoma limited to lymph node are expected in population based analysis \[[@R4]\]. In addition, it is rapidly invasive with early dissemination, and shows unpredictable pattern of metastatic spread.

Although the primary site of a CUP remains unknown in 20-50% of patient even after a full diagnostic workup \[[@R5]\], it is known that a subset of patients with CUP shows favorable clinical behavior. Identification of this group seems pivotal in the management of patients. Favorable subsets of patients accounts for about 20% of those with CUPs, and include women with papillary adenocarcinoma of the peritoneal cavity, women with adenocarcinoma involving the axillary lymph nodes, poorly differentiated carcinoma with midline distribution, poorly differentiated neuroendocrine carcinoma, squamous cell carcinoma involving cervical lymph nodes, adenocarcinoma with a colon-cancer profile, men with osteoblastic bone metastases and elevated prostate-specific antigen, isolated inguinal lymphadenopathy with squamous histology, and patients with one, small, or potentially resectable tumor \[[@R6]\].

The best approach of stepwise algorithm with immunohistochemistry (IHC) of biopsied tissue was suggested to provide a specific therapy against the most likely primary site. Although a number of recent studies discussed the use of gene expression-based tests and methylation profile in the setting of CUP, practical value of this approach in the daily clinical practice is still limited \[[@R7]-[@R10]\]. Thus, a cost-effective and systemized IHC with identification of clinicopathologic factors related with the patient prognosis are clinically relevant \[[@R11], [@R12]\]. Most of previous reported publication focused on the usage of appropriate IHC panel for the differential diagnosis. Limited number of publication described general clinical behavior and clinicopathologic factors related with them \[[@R13], [@R14]\]. In the present study, consecutive cases of CUPs from one institute were analyzed to highlight the implication of clinicopatholoic factors related with patient survival.

RESULTS {#s2}
=======

Patient demographic characteristics and clinical manifestation {#s2_1}
--------------------------------------------------------------

A total of 106 cases from 106 patients were collected from the year of 2000 to 2015. Clinicopathologic characteristics of the patients are presented in Table [1](#T1){ref-type="table"}. Median age at time of diagnosis is 59 (range: 25-83) and the number of male patients are sixty nine (65.1%). Most common histologic type was adenocarcinoma (43 cases, 40.6%), followed by squamous cell carcinoma (28 cases, 26.4%), poorly differentiated carcinoma (26 cases, 24.5%) and undifferentiated carcinoma (9 cases, 8.5%). Representative images of H-E stained section are displayed in Figure [1](#F1){ref-type="fig"}. Cases of poorly differentiated carcinoma showing neuroendocrine differentiation, confirmed by the IHC, were reported in 4 cases.

###### Clinicopathologic characteristics of patients with CUP

  Variable                          Patients N(%)(total=106)   Variable                     Patients N(%)(total=106)
  --------------------------------- -------------------------- ---------------------------- --------------------------
  **Age(years)**                                               **Bone Metastasis**          
  Median                            59(25-83)                  Absent                       78(73.6)
  \<50                              28(26.4)                   Present                      28(26.4)
  \>50                              78(73.6)                   **Treatment**                
                                                               No treatment                 19(17.9)
  **Gender**                                                   Operation                    40(37.7)
  Female                            37(34.9)                   Chemotherapy                 41(38.7)
  Male                              69(65.1)                   Radiation therapy            44(41.5)
  **Performance Status(ECOG)**                                 Concurrent chemo-radiation   16(15.1)
  0                                 13(12.6)                                                
  1                                 86(81.1)                   **CEA**                      
  2                                 4(3.8)                     Normal                       48(45.3)
  3                                 1(0.9)                     High                         32(30.2)
  4                                 2(1.9)                     Not assessed                 26((24.5)
  **Histology**                                                **CA19-9**                   
  Poorly differentiated carcinoma   26(24.5)                   Normal                       45(42.5)
  Adenocarcinoma                    43(40.6)                   High                         26(24.5)
  Squamous cell carcinoma           28(26.4)                   Not assessed                 35(33.0)
  Undifferentiated carcinoma        9(8.5)                     **CA125**                    
  **Lactate dehydrogenase(IU/L)**                              Normal                       16(15.1)
  Normal                            14(13.2)                   High                         24((22.6)
  High                              36(34.0)                   Not assessed                 66.(62.3)
  Not assessed                      56(52.8)                   **CA15-3**                   
  **CK7 immunosttinng**                                        Normal                       20(18.9)
  Negative                          27(25.5)                   High                         6(5.6)
  Positive                          60(56.6)                   Not assessed                 80(75.5)
  Not assessed                      19(17.9)                   **AFP**                      
  **CK20 Immunostaining**                                      Normal                       48(45.3)
  Negative                          77(72.6)                   High                         3(2.8)
  Positive                          10(9.4)                    Not assessed                 55(51.9)
  Not assessed                      19(17.9)                   **PIVKA-II**                 
  **CDX2 Immunostaining**                                      Normal                       18(17.0)
  Negative                          76(71.7)                   Increased                    12(11.3)
  Positive                          11(10.4)                   Not assessed                 76(71.7)
  Not assessed                      19(17.9)                   **SCCAg**                    
  **Lung Metastasis**                                          Normal                       20(18.9)
  Absent                            89(84.0)                   Increased                    8(7.5)
  Present                           17(16.0)                   Not assessed                 78(73.6)
  **Liver Metastasis**                                                                      
  Absent                            96(90.6)                   **Prognostic group**         
  Present                           10(9.4)                    Favorable                    31(29.2)
  **Brain Metastasis**                                         Non-favorable                75(70.8)
  Absent                            70(66.0)                   **Lower GI profile**         
  Present                           8(7.5)                     Lower GI profile             6(5.7)
  Symptomatically suspicous         2(1.9)                     Non-Lower GI profile         81(76.4)
  Not evaluated                     26(24.5)                   Not assessed                 19(17.9)

![Representative histological features of cancers of unknown primary origin\
Case1; Poorly differentiated carcinoma, positive for CK7 and CK20 and focal positive for CDX-2. Case2; Squamous cell carcinoma, positive for CK7. Case3; Undifferentiated carcinoma, positive for CK7 and CDX-2 and negative for CK20.](oncotarget-08-62630-g001){#F1}

About 72.6% (77 out of 106) of patients were treated by chemotherapy and radiation concurrently or sequentially. Metastasis to liver, lung, bone and brain was noted in 10 (9.4%), 17 (16.0%), 28 (26.4%) and 10 (9.4%) patients, respectively. Tumor markers at the time of diagnosis were assessed and elevated carcinoembryonic antigen (CEA), cancer antigen (CA) 19-9, CA125, CA15-3, and alpha fetoprotein (AFP) were recorded in 32 (30.2%), 26 (24.5%), 24 (22.6%), 6 (5.6%) and 3 (2.8%) patients, respectively. When CUP patients were categorized into the 'favorable' and 'non-favorable' groups based on predefined criteria, the number of cases belonging to the favorable group was 31 (29.2%), compatible with the previously known range of about 80%. Among these 19 patients (17.9%) presented as squamous cell carcinoma of the cervical lymph nodes, 4 patients presented as poorly differentiated carcinoma with neuroendocrine characteristics proven by immunohistochemistry, 6 patients with adenocarcinoma with colon-cancer profile and 2 male patients with blastic bone metastases and elevated prostate-specific antigen.

Univariate analysis of clinicopathologic factors related to the patient's survival {#s2_2}
----------------------------------------------------------------------------------

The overall survival probability for the entire CUP study patients is displayed in Figure [2](#F2){ref-type="fig"}. A total of 39 cases were censored and death event were 67 cases. Median follow up of censored patients was 26.7 months. Median survival time was 13 months (95% confidence interval \[CI\], 8.43 - 19.1 months), with one, two and five-year survival rate of 53.7%, 35.1%, and 30.5%,, respectively, which is better than reported (Figure [2](#F2){ref-type="fig"}).

![A Kaplan-Meier graph of overall survival of all patients](oncotarget-08-62630-g002){#F2}

Given the importance of the identification of subgroups with favorable clinical behavior, several clinicopathologic factors were analyzed to identify factors related with overall survival and are summarized in Table [2](#T2){ref-type="table"}, Figure [3](#F3){ref-type="fig"} and [Supplementary Figure 1](#SD1){ref-type="supplementary-material"}. Factors related with shorter overall survival was presence of bone metastasis (*P* = 0.017), metastasis not confined to the lymph nodes (*P* = 0.002), patients with no treatment (*P* \< 0.001), adenocarcinoma phenotype (*P* \< 0.001), increased CA19-9 (*P* = 0.003), increased CEA (*P* = 0.047), patients belonging to poor risk group in Culine's model (*P* \< 0.001) and increased lactate dehydrogenase (LDH, *P* \< 0.001). In the female subset, patients with axillary lymph node metastasis showed tendency of better overall survival, although not statistical significant (*P* = 0.057).

###### Univariate analysis of clinicopathologic characteristic related with overall survival

  Variable                                Patients N(%)   Event   Median survival(months)   *P* value
  --------------------------------------- --------------- ------- ------------------------- ------------
  **Age(years)**                                                                            
  \<50                                    28(26.4)        17      19                        0.2238
  \>50                                    78(73.6)        50      12                        
  **Gender**                                                                                
  Female                                  37(34.9)        24      12                        0.8384
  Male                                    69(65.1)        43      13                        
  **Performance Status(ECOG)**                                                              
  0                                       13(12.3)        6       78                        **0.0014**
  1                                       86(81.1)        57      12                        
  2                                       4(3.8)          2       2                         
  3                                       1(0.9)          0       0                         
  4                                       2(1.9)          2       1                         
  **Histology**                                                                             
  Poorly differentiated carcinoma         26(24.5)        15      18                        **0.0016**
  Adenocarcinoma                          43(40.6)        32      4                         
  Squamous cell carcinoma                 28(26.4)        15      24                        
  Undifferentiated carcinoma              9(8.5)          5       119                       
  **Lactate dehydrogenase(IU/L)**                                                           
  Normal                                  14(13.2)        4       6                         **0.0002**
  High                                    36(34.0)        27      0                         
  Not assessed                            56(52.8)                                          
  **CK7 immunosttinng**                                                                     
  Negative                                27(25.5)        17      24                        0.1111
  Positive                                60(56.6)        42      9                         
  Not assessed                            19(17.9)                                          
  **CK20 Immunostaining**                                                                   
  Negative                                77(72.6)        50      14                        **0.002**
  Positive                                10(9.4)         9       1                         
  Not assessed                            19(17.9)                                          
  **CDX2 Immunostaining**                                                                   
  Negative                                76(71.7)        51      14                        0.0418
  Positive                                11(10.4)        8       1                         
  Not assessed                            19(17.9)                                          
  **Lung Metastasis**                                                                       
  Absent                                  89(84.0)        55      2                         0.2142
  Present                                 17(16.0)        12      0                         
  **Liver Metastasis**                                                                      
  Absent                                  96(90.6)        60      13                        0.4388
  Present                                 10(9.4)         7       7                         
  **Bone Metastasis**                                                                       
  Absent                                  78(73.6)        47      15                        **0.0171**
  Present                                 28(26.4)        20      5                         
  **Brain Metastasis**                                                                      
  Absent                                  70(66.0)        38      16                        0.6027
  Present                                 8(7.5)          8       24                        
  Symptomatically suspicous               2(1.9)                                            
  Not evaluated                           26(24.5)                                          
  **Treatment**                                                                             
  No treatment                            19(17.9)        10      2                         **0.0000**
  Operation                               40(37.7)        11      6                         
  Chemotherapy                            41(38.7)        13      13                        
  Radiation therapy                       44(41.5)        15      7                         
  Concurrent chemoradiation               16(15.1)        18      34                        
  **CEA**                                                                                   
  Normal                                  48(45.3)        30      14                        **0.0468**
  High                                    32(30.2)        23      4                         
  Not assessed                            26(24.5)                0                         
  **CA19-9**                                                                                
  Normal                                  45(42.5)        25      15                        **0.0031**
  High                                    26(24.5)        21      2                         
  Not assessed                            35(33.0)                0                         
  **CA125**                                                                                 
  Normal                                  16(15.1)        13      12                        0.7652
  High                                    24(22.6)        18      4                         
  Not assessed                            66(62.3)                0                         
  **CA15-3**                                                                                
  Normal                                  20(18.9)        13      13                        0.5559
  High                                    6(5.6)          5       4                         
  Not assessed                            80(75.5)                0                         
  **AFP**                                                         **0**                     
  Normal                                  48(45.3)        31      14                        0.1506
  High                                    3(2.8)          2       0                         
  Not assessed                            55(51.9)                0                         
  **PIVKA-II**                                                                              
  Normal                                  18(17.0)        14      6                         0.6332
  Increased                               12(11.3)        9       3                         
  Not assessed                            76(71.7)                                          
  **SCCAg**                                                                                 
  Normal                                  20(18.9)        14      14                        0.6109
  Increased                               8(7.5)          6       9                         
  Not assessed                            78(73.6)                                          
  **Prognostic group**                                            **0**                     
  Favorable                               31(29.2)        19      20                        0.191
  Non-favorable                           75(70.8)        48      11                        
  **Prognostic group (by Culine)**                                                          
  Good risk                               64(60.4)        36      19                        **0.0005**
  Poor risk                               42(39.6)        31      7                         
  **Metastasis confined to lymph node**                                                     
  Yes                                     36(34.0)        16      9                         **0.0015**
  No                                      70(66.0)        51      78                        
  **Lower GI profile**                                                                      
  Lower GI profile                        6(5.7)          5       13                        0.126
  Non-Lower GI profile                    81(76.4)        54      1                         
  Not assessed                            19(17.9)                                          

![Kaplan-Meier survival estimates of CUP patients according to the clinicopathologic factors\
Adenocarcinoma histology (*P* = 0.001), increased CA19-9 (*P* = 0.003), patients belonging to poor risk group in Culine's model (*P* \< 0.001), CK20 positivity (*P* = 0.002), metastasis not confined to the lymph nodes (*P* = 0.0015), and presence of bone metastasis (*P* = 0.017) were factors related with unfavorable clinical outcome.](oncotarget-08-62630-g003){#F3}

We assessed immunohistochemical results of CK20, CK7 and CDX-2 using TMA and analyzed expression profiles related with patients' overall survival. In lower gastrointestinal profiles, patients with CK20 positive CUP had a poorer overall survival than patients with CK20 negative CUP (*P* = 0.002) and CDX-2 expression (*P* = 0.042). Patients with CK7 positive CUP also tended to have a shorter overall survival than patients with CK7 negative CUP (*P* = 0.111).

Patients belonging to favorable prognostic group showed better overall survival than unfavorable group with limited statistical significance (*P* = 0.191). In validation of Culine's prognostic model, median survival of good risk patient was 19 months whereas that of poor risk patients were 7 months (hazard ratio \[HR\], 2.45; 95% CI, 1.46 - 4.10; *P* \< 0.001).

Multivariable analysis of clinicopathologic factors related to the patient's survival {#s2_3}
-------------------------------------------------------------------------------------

For adjustment of parameters affecting a patient's survival, multivariable analysis was performed using Cox regression test (Table [3](#T3){ref-type="table"}). Multivariable analysis using adenocarcinoma histology, CK20 positivity, CA19-9 elevation, metastasis confined to lymph nodes, presence of bone metastasis and favorable group defined by Culine's prognostic model was developed. Finally, factors related with overall survival were cases belonged to Culine's poor risk group (HR, 3.88; 95% CI, 1.75-8.64; *P* = 0.001) and CK20 positivity (HR, 3.31; 95% CI, 1.42-7.70; *P* = 0.005).

###### Multivariable analysis of clinicopathologic factors related to survival

  Variable                                                                   HR     95% CI      P
  -------------------------------------------------------------------------- ------ ----------- -------
  *Culine's prognostic model*                                                                   
  Poor risk group *vs*. good risk group                                      3.88   1.75-8.64   0.001
  *Histologic subtype*                                                                          
   Adenocarcinoma *vs*. other subtypes                                       1.51   0.76-2.97   0.24
  *Lymph node metastasis*                                                                       
  Lymph node involement only *vs*. lymph node and distant organ metastasis   0.86   0.34-2.16   0.76
  *Bone metastsis*                                                                              
   Present *vs*. absent                                                      1.43   0.67-3.04   0.36
  *CA19-9 level*                                                                                
   Elevation *vs*. normal range                                              1.98   0.99-3.97   0.053
  *CK20 expression*                                                                             
   Positivity *vs*. negativity                                               3.31   1.42-7.70   0.005

DISCUSSION {#s3}
==========

The clinical presentation of CUP that showed early and usually aggressive metastatic dissemination with limited life expectancy require the identification of favorable patient groups. In the present study, a consecutive series of cases of CUPs in one institute was analyzed to identify the clinicopathologic factors related to patient survival. Limited information was provided by previous literature regarding the natural course of the disease and the biologic mechanism that explain the clinical manifestation of CUP. In the early nineties, a large series with 657 consecutive patients, reported decreased survival in cases with men, more organ site, adenocarcinoma histology, metastasis to lung, bone and pleura \[[@R14]\]. Since then, the importance of biomarkers and their identification by IHC has been extensively researched. We validated previously reported clinicopathologic factors associated with worse prognosis such as adenocarcinoma histology, multiple metastases beyond lymph nodes, bone metastases and good risk group based on Culine's prognostic model in this cohort. Several clinicopathologic factors related with adverse clinical outcome of CUPs were suggested including adenocarcinoma histology, poor performance status, multiple disseminated metastases, and elevated LDH, compatible with the results of this study, and they are summarized in Table [4](#T4){ref-type="table"}.

###### Previous studies of prognostic factors in patients with CUP

  Reference                  Number of Patients   Adverse prognostic factors                                                   
  -------------------------- -------------------- ---------------------------------------------------------------------------- ----------------------------------------------------------------------------
  Kambhu \[[@R21]\]          57                   Poor performance status                                                      Visceral metastases below the diaphragm
                                                  Visceral metastases below the diaphragm                                      
  Hainsworth \[[@R14]\]      220                  Dominant tumor location outside retroperitoneum and peripheral lymph nodes   Dominant tumor location outside retroperitoneum and peripheral lymph nodes
                                                  Number of metastatic sites (\>3)                                             Number of metastatic sites (\>3)
                                                  Elevated serum CEA                                                           Positive smoking history
                                                  Elevated serum LDH                                                           Older age
                                                  Positive smoking history                                                     
  Abbruzzese \[[@R22]\]      657                  Male                                                                         Male
                                                  Adenocarcinoma histology                                                     Adenocarcinoma histology
                                                  Number of metastatic sites                                                   Number of metastatic sites
                                                  Lung metastases                                                              Liver metastases
                                                  Liver metastases                                                             
                                                  Bone mtastases                                                               
                                                  Pleura metastases                                                            
                                                  Brain metastases                                                             
  van der Gaast \[[@R23]\]   79                   Poor performance status                                                      Poor performance status
                                                  Adenocarcinoma histology                                                     Elevated serum alkaline phosphatase
                                                  Bone mtastases                                                               
                                                  Liver metastases                                                             
                                                  Elevated serum alkaline phosphatase                                          
                                                  Serum AST                                                                    
  Culine \[[@R13]\]          150                  Performance status 2 or 3                                                    Performance status 2 or 3
                                                  Liver metastases                                                             Elevated serum LDH
                                                  Elevated serum alkaline phosephatase                                         
                                                  Elevated serum LDH                                                           
  Raghav \[[@R19]\]          47                   Number of metastatic sites \>3                                               Number of metastatic sites \>3
                                                  Elevated LDH                                                                 Elevated LDH
                                                  Lung metastases                                                              Tissue of origin not tested
                                                  First line treatment                                                         
                                                  Tissue of origin not tested                                                  

Unique findings in this cohort were the relation between expressions of biomarkers with the unfavorable clinical behaviors. CA19-9, CEA, and LDH elevation in the serum test and CK20 positivity in the tumor tissue were proven to be related with the shorter overall survival in univariate analysis. Especially, CK20 positivity was related to unfavorable overall survival in the multivariable analysis. Prognostic value of CK20 expression was validated in a subset of urothelial carcinomas and colorectal carcinomas \[[@R15]-[@R17]\]. This type of keratin, CK20, is a major cellular protein of mature enterocytes and goblet cells and specially expressed in the gastric and intestinal mucosa, suggesting that CUP with immunophenotype of enterocytes may have intrinsic aggressive biological behavior.

The potential limitation of this study is that the patient survival was not separately analyzed in the context of therapy given to each patient. Ever since new, broad spectrum antineoplastic chemotherapeutic drugs were introduced around late 1990s, combination of taxane and a platinum agent or gemcitabine and a platinum agent have been most commonly used for the treatment of the CUPs, but growing evidence showed a site-specific therapy based on the identified primary tumor type result in improved patient survival \[[@R3], [@R18]\]. In this regard, recent research showing epigenetic profile guided tumor type specific therapy showing improved overall survival compared with that in patients who received empiric therapy is astonishing \[[@R10]\]. Tests based on mRNA or miRNA profile are commercially available and they appear to show reproducible results. Although the practical use of these approaches need to be studied in the light of cost and feasibility in the clinical practice, identification of subgroups that may be eligible for site specific therapy seems to be the most important question for the improvement of survival of patient with CUP.

Prognostic model suggested by Culine was also validated in this cohort, suggesting that it would be appropriate to include this model in early clinical evaluation, considering its conciseness. Recently, Culine's model was validated in 47 cancer of unknown primary origin in adolescents (CUP-AYA) \[[@R19]\]. Nevertheless, the clinical utility of this model need to be regarded in the context of the treatment as the current NCCN guideline suggests the site-specific treatment of CUP based on the information from the work-up as best as can be done.

In conclusion, clinicopathologic factors related to the patient survival was analyzed, revealing CK20 expression, adenocarcinoma histology, multiple metastases beyond lymph nodes, bone metastases, poor risk groups based on Culine's models are factors related unfavorable outcome. Significance of these factors need to be considered in the context of eligibility of patients for the site-specific therapies.

MATERIALS AND METHODS {#s4}
=====================

Patient selection {#s4_1}
-----------------

This retrospective study was approved by the Institutional Review Board of Yonsei University Medical Center (approval number: 4-2015-0830). A total of 106 consecutive cases from 106 patients of carcinoma of unknown primary origin were collected from the archives of pathology in Severance hospital during the period of 2000 to 2015. Patient records/information were anonymized and de-identified prior to clinicopathologic analyses. Vital status of the patient was confirmed by the national tumor registry and electronic medical record of the patients.

The diagnostic inclusion criteria were adopted from the research of previously reported literatures \[[@R1], [@R20]\].

Clinically metastatic disseminated tumor

No definite increased specific serum tumor marker that can explain the lesion.

No identified primary tumor site at presentation

Limited to epithelial and undifferentiated cancers

Stratification of the patients {#s4_2}
------------------------------

To categorize the cases into 'favorable' and 'non-favorable' groups, the following criteria were adopted from literatures \[[@R6]\].

Women with papillary adenocarcinoma of the peritoneal cavity

Women with adenocarcinoma involving the axillary lymph nodes

Poorly differentiated carcinoma with midline distribution

Poorly differentiated neuroendocrine carcinoma

Squamous-cell carcinoma involving cervical lymph nodes

Adenocarcinoma with a colon-cancer profile (CK20+, CK7-, CDX2+)

Men with blastic bone metastases and elevated prostate-specific antigen (adenocarcinoma)

Isolated inguinal adenopathy (squamous carcinoma)

Patients with one small, potentially resectable tumour

In addition, Culine's prognostic model was applied and we classified the patients into group with good risk (ECOG performance status of 0 or 1 and normal LDH or no evidence of liver metastases if LDH is unknown) and poor risk (ECOG performance status of 2 or more or elevated LDH or presence of liver metastases if LDH unknown) \[[@R13]\].

Generation of tissue microarray {#s4_3}
-------------------------------

A representative area of H&E stained slides of each tumor and the corresponding spot was marked on the paraffin block. The area was punched out by the biopsy needle and a 3-mm tissue core was placed into a recipient block. More than 2 tissue cores were extracted to minimize extraction bias. Each tissue core was assigned.

Immunohistochemistry {#s4_4}
--------------------

We used a two-step strategy of IHC to assess CUPs according NCCN Guidelines \[[@R1]\]. First, we identified that tumors with occult primary tissue of origin were carcinomatous tumors using the following antibodies: broad spectrum cytokeratin (CK), S-100 protein, HMB45, and CD45. Next, staining for CK7 and CK20 is used to subtype carcinomas. We also used CDX-2 antibody because a recent report presented that patients with CUPs with lower gastrointestinal profile (CDX-2+, CK20+, CK7-) may have benefit from site-specific therapy \[[@R18]\]. Neuroendocrine differentiation was identified using IHCs for synaptophysin, chromogranin and CD56 in cases with histology with organoid arrangement such as solid/nesting, trabecular or gyriform pattern. Information of primary antibodies is presented as [Supplementary Table 1](#SD1){ref-type="supplementary-material"}.

Formalin-fixed, paraffin-embedded tissue sections from the tissue microarray were prepared for IHC. Briefly, 5-*μ*m-thick sections were obtained with a microtome, transferred into adhesive slides, and dried at 62°C for 30 minutes. IHC was performed using an automated staining instrument (Ventana Discovery^®^ XT, Ventana Medical System, AZ, USA) according to instruction.

Statistics {#s4_5}
----------

Patients and tumor characteristics including age, gender, histologic type, treatment, immunohistochemistry against CK7, CK20 and CDX2, tumor markers (CEA, CA19-9, CA 12-5, CA 15-3, SCCAg, AFP, PIVKA-II), site of metastases were summarized using frequencies and percentages. Analysis of overall survival was performed using Kaplan-Meier's method and log-rank tests. For adjustment of parameters affecting a patient's survival, multivariable analysis was performed using Cox regression test. We checked the proportionality assumption of each variable using stphplot function of STATA software. Statistical significance was reached when *P* \< 0.05. Data were analyzed using TitleIBM Corp. Released 2013. IBM SPSS Statistics for Windows, Version 22.0. Armonk, NY: IBM Corp.23 and Stata Statistical Software: Release 14. College Station, TX: StataCorp LP.
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